SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,986,421 | -11.2% | 550,029 | +28.0% | 0.00% | 0.0% |
| Q2 2023 | $8,994,039 | -61.1% | 429,720 | -60.7% | 0.00% | -50.0% |
| Q1 2023 | $23,101,986 | +507.7% | 1,093,844 | +632.3% | 0.00% | – |
| Q4 2022 | $3,801,442 | -0.2% | 149,369 | -5.8% | 0.00% | -100.0% |
| Q3 2022 | $3,810,000 | -32.1% | 158,571 | -45.6% | 0.00% | 0.0% |
| Q2 2022 | $5,611,000 | -53.7% | 291,677 | -58.2% | 0.00% | -50.0% |
| Q1 2022 | $12,126,000 | +99.6% | 697,701 | +151.4% | 0.00% | +100.0% |
| Q4 2021 | $6,074,000 | +25.6% | 277,476 | +9.6% | 0.00% | 0.0% |
| Q3 2021 | $4,837,000 | +476.5% | 253,139 | +417.7% | 0.00% | – |
| Q2 2021 | $839,000 | -23.8% | 48,896 | -0.7% | 0.00% | – |
| Q1 2021 | $1,101,000 | -19.2% | 49,247 | -19.6% | 0.00% | – |
| Q4 2020 | $1,362,000 | +115.2% | 61,235 | +42.8% | 0.00% | – |
| Q3 2020 | $633,000 | -71.5% | 42,873 | -71.4% | 0.00% | – |
| Q2 2020 | $2,223,000 | +186.5% | 150,065 | +112.1% | 0.00% | – |
| Q1 2020 | $776,000 | -7.7% | 70,764 | -26.1% | 0.00% | – |
| Q4 2019 | $841,000 | +23.1% | 95,741 | +4.8% | 0.00% | – |
| Q3 2019 | $683,000 | +20.7% | 91,378 | +50.5% | 0.00% | – |
| Q2 2019 | $566,000 | +58.5% | 60,698 | -10.8% | 0.00% | – |
| Q1 2019 | $357,000 | -47.1% | 68,079 | -55.1% | 0.00% | – |
| Q4 2018 | $675,000 | -69.0% | 151,496 | -43.8% | 0.00% | -100.0% |
| Q3 2018 | $2,178,000 | +27.4% | 269,595 | +10.7% | 0.00% | – |
| Q2 2018 | $1,709,000 | -50.0% | 243,552 | +1.4% | 0.00% | -100.0% |
| Q1 2018 | $3,419,000 | +46.9% | 240,266 | -9.5% | 0.00% | 0.0% |
| Q4 2017 | $2,327,000 | -19.8% | 265,601 | +7.1% | 0.00% | 0.0% |
| Q3 2017 | $2,901,000 | +65.9% | 247,914 | +98.0% | 0.00% | 0.0% |
| Q2 2017 | $1,749,000 | -46.9% | 125,215 | -47.8% | 0.00% | 0.0% |
| Q1 2017 | $3,292,000 | +492.1% | 239,974 | +209.0% | 0.00% | – |
| Q4 2016 | $556,000 | +104.4% | 77,656 | +332.9% | 0.00% | – |
| Q3 2016 | $272,000 | +1260.0% | 17,937 | +746.9% | 0.00% | – |
| Q2 2016 | $20,000 | -56.5% | 2,118 | -39.1% | 0.00% | – |
| Q1 2016 | $46,000 | – | 3,479 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |